和黄医药(00013.HK)启动HMPL-A580临床试验 首名患者已接受首次给药

阿斯达克财经
Mar 04

和黄医药(00013.HK) 公布,在中国和美国启动公司第二款抗体靶向偶联药物(ATTC)HMPL-A580用于治疗不可切除的晚期或转移性实体瘤的I/IIa期临床试验。首名患者已于今日(4日)于接受首次给药治疗。(ss/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-04 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10